Rapid Micro Biosystems (NASDAQ:RPID) CFO Sells $32,313.60 in Stock

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) CFO Sean Wirtjes sold 7,480 shares of the business’s stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $4.32, for a total value of $32,313.60. Following the sale, the chief financial officer owned 556,194 shares of the company’s stock, valued at approximately $2,402,758.08. The trade was a 1.33% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Rapid Micro Biosystems Trading Down 21.9%

Rapid Micro Biosystems stock traded down $0.96 during mid-day trading on Thursday, hitting $3.42. The stock had a trading volume of 514,590 shares, compared to its average volume of 133,521. The stock has a 50-day simple moving average of $3.97 and a two-hundred day simple moving average of $3.54. The company has a current ratio of 4.23, a quick ratio of 2.95 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $151.58 million, a PE ratio of -3.39 and a beta of 1.38. Rapid Micro Biosystems, Inc. has a 12 month low of $1.86 and a 12 month high of $4.94.

Rapid Micro Biosystems (NASDAQ:RPID) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.05). Rapid Micro Biosystems had a negative return on equity of 73.90% and a negative net margin of 145.11%.The firm had revenue of $11.28 million for the quarter, compared to the consensus estimate of $10.93 million. As a group, sell-side analysts forecast that Rapid Micro Biosystems, Inc. will post -1.1 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on RPID shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research note on Thursday, January 22nd. Wall Street Zen raised Rapid Micro Biosystems from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Rapid Micro Biosystems presently has a consensus rating of “Hold” and a consensus price target of $8.00.

Institutional Trading of Rapid Micro Biosystems

A number of hedge funds have recently modified their holdings of the company. Hudson Bay Capital Management LP bought a new position in Rapid Micro Biosystems during the 3rd quarter worth approximately $38,000. American Century Companies Inc. boosted its position in shares of Rapid Micro Biosystems by 46.1% during the second quarter. American Century Companies Inc. now owns 16,922 shares of the company’s stock worth $58,000 after purchasing an additional 5,341 shares in the last quarter. Fifth Lane Capital LP bought a new position in shares of Rapid Micro Biosystems during the fourth quarter worth $51,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Rapid Micro Biosystems in the 4th quarter valued at $71,000. Finally, Barclays PLC bought a new stake in shares of Rapid Micro Biosystems in the 4th quarter valued at $72,000. 52.60% of the stock is currently owned by institutional investors and hedge funds.

More Rapid Micro Biosystems News

Here are the key news stories impacting Rapid Micro Biosystems this week:

• Positive Sentiment: New multi-system order from Samsung Biologics reinforces commercial traction for the Growth Direct automation platform and expands deployment across a large CDMO customer network — a clear revenue-growth catalyst. Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics
• Positive Sentiment: Company reported record Q4 and full‑year 2025 revenue (Q4 revenue $11.3M, FY2025 $33.6M), and Q4 revenue beat the Street — evidence demand and placements are growing. Rapid Micro Biosystems Reports Record Fourth Quarter and Full-Year 2025 Financial Results
• Neutral Sentiment: Earnings call transcript and summaries provide color on growth initiatives and customer pipeline but did not materially change the near‑term outlook; read for management commentary on placements, margin drivers and execution risks. Rapid Micro Biosystems, Inc. (RPID) Q4 2025 Earnings Call Transcript
• Negative Sentiment: EPS missed expectations (reported ($0.28) vs. consensus ($0.23)), and profitability remains weak (large negative net margin and negative ROE) — these metrics keep the stock in a riskier profile and may slow multiple expansion. RPID Earnings / Conference Call
• Negative Sentiment: The company issued FY2026 revenue guidance of $37.0M–$41.0M (management expects ~30–38 system placements) — the midpoint is slightly below consensus (~$39.7M), which, combined with high operating losses, likely weighed on sentiment. 2026 Guidance in Press Release
• Negative Sentiment: Recent insider selling by CEO, CFO and COO (multiple Form 4 filings show sales in March) can amplify downward pressure on the stock even if sales are for diversification or liquidity. SEC Form 4 — Spignesi sale

About Rapid Micro Biosystems

Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company’s technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.

In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.